A Novel HNRNPC‐RARA Fusion in Acute Promyelocytic Leukaemia Lacking PML‐RARA Rearrangement, Sensitive to Venetoclax‐based Therapy

Meng Liu,Xiang‐Yu Zhao,Weiqiang Pan,Zhiliang Qian,Mengbao Du,L. Wang,He Huang,Haowen Xiao

DOI: https://doi.org/10.1111/bjh.17642

2021-01-01

British Journal of Haematology

Abstract:The vast majority of acute promyelocytic leukaemia (APL) is characterised by the balanced translocation t (15;17) (q22; q12) resulting in the fusion transcript promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARA). Rare cases with APL are found to bear translocations with RARA fused with other partner genes including promyelocytic leukaemia zinc finger protein (PLZF), nucleophosmin 1 (NPM1), nuclear mitotic apparatus protein (NUMA), signal transducer and activator of transcription 5b (STAT5b), STAT3, protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A), factor interacting with PAPOLA and CPSF1 (FIP1L1), B-cell lymphoma 6 (BCL-6) co-repressor (BCOR), oligonucleotide/oligosaccharide-binding fold-containing protein 2A (OBFC2A), transducin beta-like 1 X-linked receptor 1 (TBLR1), general transcription factor IIi (GTF2I), interferon regulatory factor 2 binding protein 2 (IRF2BP2) and fibronectin type III domain containing 3B (FNDC3B). In the present study, we report a novel fusion gene involving the heterogeneous nuclear ribonucleoprotein C (HNRNPC) gene and the RARA gene identified in an APL patient lacking t(15;17) (q22;q12)/PML-RARA fusion. The study was approved by the Ethics Committee of Sir Run Run Shaw Hospital at Zhejiang University School of Medicine. The patient gave her written informed consent. In December 2019, a 29-year-old woman was admitted to our hospital due to fever and lower back pain. Her blood analysis showed a white blood cell count of 10 5 9 10/l, a haemoglobin level of 57 g/l, a platelet count of 65 9 10/l and 5% blasts. Prothrombin time and activated partial thromboplastin time were within the normal range. Fibrinogen and Ddimer levels were 0 7 g/l (reference range 2–4 g/l) and 6 9 lg/ ml (reference <0 5 μg/ml) respectively. A bone marrow (BM) smear showed an infiltration by 91% of atypical hypergranular promyelocytes, and no Auer rod was found in the patient’s promyelocytes (Fig 1A). Further flow cytometry revealed that these cells were positive for cluster of differentiation (CD)13, CD33, CD117 and cytoplasmic myeloperoxidase (cMPO), partially expressed CD64, human leukocyte antigen-DR isotype (HLA-DR), CD9 and CD123 and were negative for CD16, CD11b, CD34 and other Tor B-lymphoid-related markers, which is consistent with the phenotype of abnormal promyelocytes. The presumptive diagnosis of this patient was APL. However, interphase fluorescence in situ hybridisation (FISH) using the PML-RARA dual-colour dual-fusion translocation probes, nuc ish (PML, RARA)92(PML con RARA91), failed to detect the PML-RARA rearrangement in 400 nuclei of the patient’s BM cells (Fig 1B). The karyotype analysis revealed 46, XX [20] (Fig 1C). Moreover, detection of PML-RARA or PLZF-RARA fusion by fluorescent reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was also negative. The multiplex fluorescent qualitative RT-PCR, targeting 51 leukaemia-related translocations/chromosomal abnormalities (Table SI) including the PML-RARA (bcr1, bcr2, bcr3), BCOR-RARA, FIP1L1-RARA, PLZF-RARA, NUMA1-RARA, nucleoporin 98 and 96 precursor (NUP98)-RARA and STAT5B-RARA fusion transcripts, were all negative. To search for potential rearrangements involving the RARA or retinoic acid receptor-b (RARB) or retinoic acid receptor-c (RARG) genes, we used the patient’s BM sample collected at diagnosis to perform whole transcriptome RNA sequencing (RNA-Seq) analysis using Illumina HiSeq X (llumina, San Diego, CA, USA). Two types of novel RARA fusion transcripts were detected. The major fusion transcript involved the HNRNPC gene and the RARA gene. RNA-Seq results revealed one breakpoint in intron 3 of the HNRNPC gene and one breakpoint in intron 2 of the RARA gene (Fig 1D). The 50 region of the HNRNPC gene (from exon 1 to exon 3) (NM_031314) was fused in frame with the 50 region of the RARA gene (from exon 3 to exon 9) (NM_000964.4) (Fig 1D). Another minor fusion transcript involving the RARA gene and the HNRNPC pseudogene 2 (HNRNPCP2). RNA-Seq results revealed one breakpoint in intron 8 of the RARA gene and the 50 region of the RARA gene (from exon 1 to exon 8) (NM_000964.4) was fused in frame with the 50 region of the HNRNPCP2 gene [from nucleotide sequences 409–1722 base pairs (bp)] (NG_006653) (Fig 1E). For validation of two novel fusions, RT-PCR using complementary DNA was performed, and the following primers were designed to amplify HNRNPC-RARA mRNA: forward (at HNRNPC exon 3), 50-ATTGGGAATCTCA A-30, and reverse (at RARA exon 3), 50TCAGGCTACCACTATGGG-30. The following primers were used to amplify RARA-HNRNPCP2 mRNA: forward (at RARA exon 8), 50-GGTCTACGTGCGGAAGC-30, and reverse (at HNRNPCP2: c.568–585), 50-CAGCCCGAGCAATAGGAG30. The expected bands of approximately 300 bp (HNRNPCRARA) and 270 bp (RARAHNRNPCP2) were visualised by electrophoresis (Fig 1F), and the PCR product was analysed Correspondence